Litcius/Paper detail

651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study

M.R. Dzienis, J.E. Cundom, Christian Sebastian Fuentes, A.R. Hansen, M.J. Nordlinger, A.V. Pastor, P. Oppelt, A. Neki, R.W. Gregg, I.P. Figueiredo Lima, F.A. Franke, G.F. da Cunha, J.E. Tseng, T. Loree, A.J. Joshi, J.S. Mccarthy, N. Naicker, Y. Sidi, B. Gumuscu, G. De Castro

2022Annals of Oncology21 citationsDOI

Topics & Concepts

MedicineTolerabilityPembrolizumabCarboplatinInternal medicineClinical trialOncologyHead and neck squamous-cell carcinomaPhases of clinical researchSurgeryHead and neck cancerRadiation therapyCancerChemotherapyCisplatinAdverse effectImmunotherapyCancer Immunotherapy and BiomarkersBrain Metastases and TreatmentLung Cancer Treatments and Mutations
651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study | Litcius